Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1331832 | 0.83 | MAPT (0.35) | TRPV1NFE2L2KDM4EMPIL3MBTL1 | |
| SCHEMBL23126660 | 0.83 | ACSS2 (0.36) | TRPV1NFE2L2KDM4EMPIL3MBTL1 | |
| SCHEMBL12293799 | 0.83 | MAPT (0.35) | TRPV1NFE2L2KDM4EMPIL3MBTL1 | |
| SCHEMBL18506051 | 0.81 | ACSS2 (0.33) | TRPV1NFE2L2KDM4EMPIL3MBTL1 | |
| SCHEMBL22113840 | 0.79 | TDP1 (0.35) | TRPV1NFE2L2L3MBTL1ACSS2 | |
| SCHEMBL3914027 | 0.79 | NFE2L2 (0.33) | TRPV1NFE2L2KDM4EMPIL3MBTL1 | |
| SCHEMBL9065844 | 0.79 | NFE2L2 (0.38) | NFE2L2KDM4EMPIL3MBTL1HTT | |
| SCHEMBL30345232 | 0.79 | NFE2L2 (0.38) | NFE2L2KDM4EMPIL3MBTL1HTT | |
| SCHEMBL24608544 | 0.78 | ACSS2 (0.34) | TRPV1KDM4EMPIL3MBTL1ALDH1A1 | |
| SCHEMBL24608546 | 0.78 | NFE2L2 (0.37) | TRPV1NFE2L2MAPTHTTACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | UNIVERSITY OF OULU (FI) | 2023-10-12 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | CELLECTIS (FR) | 2010-01-28 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7262210-B2 | Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-28 | — | — | US | disclosed |
| US-7262210-B2 | Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-28 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | TRPV1 4187/4885NFE2L2 3308/4885KDM4E 1096/4885 |
| US-20230322721-A1 | TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS | CBR3, GBA3, TECR | TRPV1 3268/4885NFE2L2 1935/4885KDM4E 3349/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | TRPV1 4816/4885NFE2L2 1565/4885KDM4E 1713/4885 |
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | TRPV1 1970/4885NFE2L2 2700/4885KDM4E 3134/4885 |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | BCLAF1, EED, BCL3 | TRPV1 4880/4885NFE2L2 365/4885KDM4E 410/4885 |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | TGFB1, TGFB2, TGFBR1 | TRPV1 4686/4885NFE2L2 259/4885KDM4E 2588/4885 |
| US-20070167443-A1 | Substituted quinolones and methods of use | TOP2A, NQO2, TOP2B | TRPV1 4795/4885NFE2L2 948/4885KDM4E 2670/4885 |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | TRPV1 398/4885NFE2L2 86/4885KDM4E 2311/4885 |
| US-20100022550-A1 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | AR, SHBG, CYP17A1 | TRPV1 305/4885NFE2L2 3595/4885KDM4E 2157/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | TRPV1 4779/4885NFE2L2 2428/4885KDM4E 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.